TNFRSF1B and ovarian carcinoma: C. Govindaraj et al., on the other hand, discovered that targeting and reducing the highly immunosuppressive TNFR2+ Tregs within ovarian cancer patients, could potentially disrupt numerous immunoregulatory circuits within the tumour microenvironment and therefore improve response to treatment [11].